



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)

Tel. : (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

Date: 13th November, 2025

To,

The Secretary,
Department of Corporate Services,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400001

Scrip Code: 524606

Sub.: Disclosure of Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30th September, 2025

Dear Sirs,

Pursuant to Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its Board Meeting held on 13th November, 2025 has approved the Unaudited Financial Results of the Company for the Quarter ended 30th September, 2025 and Limited Review Report by the Auditors for the unaudited Financial Results of the Company for the Quarter ended on 30th September, 2025.

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited


Sudhir Sethi
Chairman & Director
DIN: 00090172



Subhash Chand Jain Anurag & Associates

Chartered Accountants

104, Archana Apartment, 8-B, Ratlam Kothi, Indore-452001 (MP)

PH # 2519439, 2527682 FAX # 0731 2519116

Mob. No. : +91-9302123882

Email: scjainca2004@yahoo.com



Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

The Board of Directors

Beryl Drugs Limited

133, Kanchan Bagh Colony,

Indore (M.P.)-452001

1. We have reviewed the accompanying statement of unaudited financial results of **Beryl Drugs Limited** ("the Company") for the quarter ended September 30, 2025 and the year to date result for the period from April 01, 2025 to September 30, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended (the "Listing Regulations").
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standard) rules 2015, as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain




assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33, Regulation 52 and Regulation 54 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. Attention is drawn to Notes to the statement:
- a) **Note No. 7:** A part of the manufacturing facility is currently under suspension and upgradation as per order of state FDA. However, The Company has submitted a point-wise rectification/compliance statement along with supporting documents and photographs in response to the notice issued by the Food and Drugs Administration. Nevertheless, Production has not yet commenced as the inspection by the officials of the Food and Drugs Administration is still pending.

Date : 13/11/2025
Place: Indore

For Subhash Chand Jain Anurag & Associates
Chartered Accounts
FRN: 004733C




(Akshay Jain)
Partner
M.No.447487
UDIN: 25447487BMIDJX4907

Beryl Drugs Limited

CIN : L02423MP1993PLC007840

Registered Office : 133, Kanchan Bagh Colony, Indore (M.P.)-452001

Statement of Cash Flow for the Six Month ended on 30th September 2025

S. No. Particulars	For the six month 30-09-2025 Unaudited	For the six month 30-09-2024 Unaudited	(Rs. In lacs) For the year ended 31-03-2025 Audited
A Cash Flow from Operating Activities			
1 Profit Before Tax			
Add : Depreciation, Amortization and Impairment	33.00	60.33	86.57
Add : Finance Cost	77.23	61.65	124.56
Less : Rental Income	18.11	33.03	52.97
Less : Dividened Received	-6.68	-6.68	-13.37
Less : Acturial gain of PVBDO	0	0.00	0.00
Less : Profit on sales of fixed Assets	0	0.18	0.00
Less : Capital Gain on Sale of Shares	0	0.00	0.00
	0	0.00	0.00
2 Operating Profit Before Working Capital Changes	00.00	148.51	250.73
3 Adjustment for : (Increase) / Decrease in Operating Assets			
Inventories			
Trade Receivables	-86.02	-0.24	-64.26
Other Financial Assets	123.78	33.25	212.69
Other Non Current Assets	-2.59	38.32	39.10
Other Current Assets	0.43	32.34	-44.58
	-31.5	53.70	-2.52
Increase/(Decrease) in Operating Liabilities and Provisions			
Provisions			
Trade Payables	2.89	3.82	7.45
Other Financial Liabilities	74.13	-124.49	-90.05
Other Current Liabilities	16.18	12.83	-8.49
	9.21	51.21	-18.41
4 Cash Flow used in Operations			
Payment of Income Tax	228.17	249.25	281.66
Net Cash Used in Operating Activities (A)	-12.46	-11.12	-18.00
	215.71	238.13	263.66
B Cash Flow from Investing Activities			
1 Purchase of Property Plant and Equipments (PPE)			
2 Proceeds from Government Grant in respect of tangible assets	-301.82	-160.07	-218.51
3 Proceeds from Sales of Tangible Assets			
4 Capital Advances and Others	0	0.00	90.44
5 Proceeds from Sales of Investments	0	0.00	0.00
6 Rental Income	0	0.00	75.00
7 Bank Balances other than Cash & Cash Equivalents	6.68	6.68	0.00
8 Payment of Liabilities Held for Sale	0	-0.01	13.37
9 Dividend Income	0	0.00	0.00
	0	0.00	0.00
Net Cash Used in Investing Activities (B)	-295.14	-153.40	-39.70
C Cash Flow from Financing Activities			
1 Changes in Short Term Borrowings			
2 Proceeds from Long Term Borrowings	39.65	-73.43	-36.22
3 Repayment of Long Term Borrowings	0	0.00	124.84
4 Finance Costs	-16.87	17.17	-190.66
5 Loans Given	-18.11	-33.03	-52.97
6 Receipt of Loan Given	0	0.00	0.00
	0	0.00	0.00
Net Cash Used in Financing Activities (C)	4.67	-89.29	-155.01
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	-74.76	-4.56	68.95
Cash and Cash Equivalents at the Beginning of the Year	81.44	12.49	12.49
Cash and Cash Equivalents at the End of the Year	6.68	7.93	81.44
Components of Cash and Cash Equivalents:			
Cash on Hand	6.06	7.87	5.26
Balance with bank in Current Account	0.62	0.06	1.18
Fixed Deposit having maturity less than 3 months	0	0.00	75.00
	6.68	7.93	81.44

For and on behalf of the Board of Directors

Date: 13/11/2025
Place: Indore



Sanjay Sethi
Sanjay Sethi
Managing Director
DIN : 00090277



BERYL DRUGS LIMITED

ANNEXURE I

Part I Submission of Unaudited Financial Result by Companies Other than Banks


Statement of standalone Unaudited Result for the Quarter/half year ended 30/09/2025 (Rs in lacs)

Particulars	Quarter ended			Half year ended		Year ended Previous year ended (31-03-2025)
	3 months ended (30-09-2025)	Preceding 3 months ended (30-06-2025)	Corresponding 3 months ended in the previous year (30-09- 2024)	Year to date figures for current period ended (30-09-2025)	Year to date figures for previous period ended (30-09-2024)	
1 Income	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(a) Revenue From Operations						
Net sales or Revenue from Operations						
Other operating revenues	512.00	479.43	561.42	991.43	1186.33	2114.62
Total Income	3.66	4.15	3.10	7.81	6.92	140.85
2 Expenses	515.66	483.58	564.52	999.24	1193.25	2255.48
(a) Cost of materials consumed						
(b) Purchases of stock-in-trade	278.90	220.87	266.75	499.77	602.89	1112.14
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
(d) Employee benefit expense	-20.76	-18.34	1.35	-39.10	10.46	-33.70
(e) Finance costs	57.68	53.39	50.13	111.07	99.77	221.22
(f) Depreciation and amortisation expense	8.02	10.09	12.26	18.11	33.03	52.97
(g) Other Expenses	39.15	38.08	33.48	77.23	61.65	124.56
Total expenses	126.64	172.52	189.78	299.16	325.11	691.72
3 Profit before tax (1-2)	489.63	476.61	553.75	966.24	1132.91	2168.92
4 Tax Expense	26.03	6.97	10.77	33.00	60.34	86.56
Current tax						
Mat Credit Entitlement	10.66	15.00	12.43	25.66	26.18	20.11
Adjustments in respect of current income tax of prior years	0.00	0.00	0.00	0.00	0.00	0.00
Deferred tax	0.68	0.00	0.00	0.68	0.00	-1.09
Total Tax Expenses	13.80	-10.14	-2.35	3.66	-3.32	9.66
5 Profit after tax (3- 4)	25.14	4.86	10.08	30.00	22.86	28.68
Other comprehensive income	0.89	2.11	0.69	3.00	37.48	57.88
6 Total Comprehensive Income	-0.24	0.24	0.25	0.00	0.52	0.16
7 Details of equity share capital	0.65	2.35	0.94	3.00	38.00	58.05
Paid-up equity share capital						
Face value of equity share capital	507.17	507.17	507.17	507.17	507.17	507.17
8 Earnings per share	10.00	10.00	10.00	10.00	10.00	10.00
(a) Basic earnings per share before extraordinary items	0.02	0.04	0.01	0.06	0.74	1.14
(b) Diluted earnings per share before extraordinary items	0.02	0.04	0.01	0.06	0.74	1.14

Notes:

- The above financial results have been prepared in accordance with the recognition and measurement principles stated therein prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India
- The above results for the quarter ended 30th September 2025 which have been subjected to Limited Review by Statutory Auditors of the Company were reviewed and recommended by the Audit Committee and subsequently by the Board of Directors at its meeting held on 14th Nov.2022 in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015.
- The Income from Operations is from one segment namely "Pharmaceutical Industry".
- The figures for the previous periods have been regrouped, wherever necessary.
- Depreciation is provided on Written down value method on the estimated remaining useful lives of the assets.
- The Company has considered internal and external information upto the date of approval of these financial results in assessing the recoverability of financial and non financial assets, based on which it expects to recover the carrying amount of these assets. The eventual outcome of impact of global health pandemic may be different from those estimated as on the date of approval of these financial results,
- A part of the manufacturing facility is currently under suspension and upgradation as per order of state FDA. However, The Company has submitted a point-wise rectification/compliance statement along with supporting documents and photographs in response to the notice issued by the Food and Drugs Administration. Nevertheless, Production has not yet commenced as the inspection by the officials of the Food and Drugs Administration is still pending.
- The Company has incurred on upgradation of Plant out of recovery of Debtors and OD as well as some payments payable due to suppliers.
- Earnings per Share amount is Shown in Rupees.
- The above results were taken on record at the meeting of the board of director held on November 13th, 2025.

For and on behalf of the Board of Directors
For Beryl Drugs Limited



Sanjay Sethi
Managing Director
DIN : 00090277

Date: 13/11/2025
Place: Indore

BERYL DRUGS LIMITED
133, KANCHAN BAGH INDORE (M.P.)
CIN: L02423MP1993PLC007840

UNAUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30th SEPTEMBER 2025

PARTICULARS	(Rs. In Lacs)		
	As At 30/09/2025 (Unaudited)	As At 30/09/2024 (Unaudited)	As At 31/03/2025 (Audited)
ASSETS			
Non-Current Assets			
Property Plant and Equipment			
Capital Work-in-Progress	739.75	706.38	600.46
Investment Property	82.72	00.00	0.00
Other Intangible Assets	22.18	20.38	19.59
Financial Assets	0.07	00.09	0.07
Investments			
Trade Receivables	0.00	00.00	0.00
Loans	0.00	00.00	0.00
Other Financial Assets	0.00	00.00	0.00
Deferred Tax Assets (Net)	33.14	09.83	23.89
Other Non-Current Assets	0.00	13.46	0.61
Total Non-Current Assets	46.49	18.63	46.92
Current Assets	924.35	768.78	691.54
Inventories			
Financial Assets	276.30	154.26	190.28
Investments			
Trade Receivables	0.00	00.00	0.00
Cash and cash equivalents	421.93	725.14	545.71
Bank Balance other than above	6.68	07.93	81.44
Loans	0.00	00.00	0.00
Other Financial Assets	0.00	00.00	0.00
Current Tax Asset (Net)	6.21	54.10	12.87
Other Current Assets	0.00	00.00	0.00
Assets held for Sale	105.66	17.95	74.16
Total Current Assets			0.00
Total Assets	816.78	959.37	904.46
	1741.13	1728.15	1596.00
EQUITY AND LIABILITIES			
Equity			
Equity Share capital			
Other Equity	509.37	509.37	509.37
Total Equity	437.48	444.51	441.01
	946.85	953.88	950.37
Liabilities			
Non-Current Liabilities			
Financial Liabilities			
Borrowings			
Provisions	156.71	257.53	173.58
Deferred Tax Liabilities (Net)	52.30	42.21	42.04
Other Non-Current Liabilities	0.75	00.00	0.00
Total Non-Current Liabilities	0.00	00.00	0.00
Current Liabilities	209.76	299.74	215.62
Financial Liabilities			
Borrowings			
Trade payables	273.42	195.59	233.77
: Outstanding dues of Micro, Small and Medium Enterprises			
: Outstanding dues of creditors other than MSME	21.21	23.78	38.94
Other Financial Liabilities	164.47	53.34	72.61
Other Current Liabilities	38.81	43.95	22.63
Provisions	47.28	107.69	38.07
Liabilities Classified held for sale	14.86	08.44	11.97
Current Tax Liabilities (Net)	0.00	00.00	0.00
Total Current Liabilities	24.47	41.75	12.01
Total Liabilities	584.52	474.53	430.00
Total Equity and Liabilities	794.28	774.27	645.62
	1741.13	1728.15	1596.00

For and on behalf of the Board of Directors
For Beryl Drugs Limited



SANJAY SETHI
(MANAGING DIRECTOR)
DIN:00090277

Date: 13/11/2025
Place: Indore